Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey - 16/04/14
, Hervé Bachelez, MD, PhD b, Jonathan Barker, MD, FRCP, FRCPath c, Giampiero Girolomoni, MD d, Arthur Kavanaugh, MD e, Richard G. Langley, MD, FRCPC, FACP f, Carle F. Paul, MD, PhD g, Lluís Puig, MD, PhD h, Kristian Reich, MD i, Peter C.M. van de Kerkhof, MD, PhD jAbstract |
Background |
Available psoriasis surveys offer valuable information about psoriasis and psoriatic arthritis (PsA), but are limited by methodology or enrollment requirements.
Objective |
To further the understanding of the unmet needs of psoriasis and PsA patients.
Methods |
This was a large, multinational, population-based survey of psoriasis and/or PsA patients in North America and Europe. Patients were selected by list-assisted random digit dialing and did not have to currently be under the care of a health care provider, a patient organization member, or receiving treatment; 139,948 households were screened and 3426 patients completed the survey.
Results |
The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe. Psoriasis patients indicated that their most bothersome signs or symptoms were itching (43%), scales (23%), and flaking (20%). Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only. Of patients who had received oral or biologic therapy, 57% and 45%, respectively, discontinued therapy, most often for safety/tolerability reasons and a lack/loss of efficacy.
Limitations |
The survey lacked a control group, did not account for ethnic and health care system differences across countries, and was limited by factors associated with any patient survey, including accurate recall and interpretation of questions.
Conclusions |
Several identified unmet needs warrant additional attention and action, including improved severity assessment, PsA screening, patient awareness, and treatment options.
Le texte complet de cet article est disponible en PDF.Key words : health survey, patient satisfaction, psoriasis, psoriatic arthritis, quality of life, questionnaires
Abbreviations used : BSA, DLQI, HAQ-8, HCP, MAPP, PCP, PsA, QOL, RDD
Plan
| Survey sponsored by Celgene Corporation. |
|
| The authors received editorial support in the preparation of the manuscript from Peloton Advantage, LLC, and Jennifer Schwinn, RPh, funded by Celgene Corporation. Dr Lebwohl has served as an investigator for Amgen, Celgene Corporation, Coronado Biosciences, Eli Lilly and Company, Janssen Biotech, Inc, LEO Pharma, GlaxoSmithKline, and Ranbaxy Inc, and as a consultant for Abbott Laboratories, Amgen, Anacor Pharmaceuticals, Inc, BioLineRx, Ltd, Celgene Corporation, DermiPsor Ltd, Eli Lilly and Company, Galderma, Janssen Biotech, Inc, LEO Pharma, Maruho Co, Ltd, Meda Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Valeant Pharmaceuticals. Dr Bachelez has served on the advisory board of and as a consultant and speaker for AbbVie Pharmaceuticals, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, LEO Pharma, Novartis Pharmaceuticals Corporation, and Pfizer Inc, and on the advisory board of Boehringer Ingelheim. Dr Barker has no conflicts of interest to declare. Dr Girolomoni has served as an investigator for Celgene Corporation, MSD, Novartis Pharmaceuticals Corporation, and Pfizer Inc; on the advisory board of Almirall and Otsuka Pharmaceutical Co, Ltd; and on the advisory board of and as a speaker for AbbVie Pharmaceuticals, Janssen Pharmaceuticals, LEO Pharma, MSD, Novartis Pharmaceuticals Corporation, and Pfizer Inc. Dr Kavanaugh has served as an investigator for AbbVie Pharmaceuticals, Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, and UCB, Inc. Dr Langley has served on the advisory board of and as an investigator and speaker for AbbVie Pharmaceuticals, Amgen, Celgene Corporation, Centocor, Pfizer Inc, Novartis Pharmaceuticals, and LEO Pharma. Dr Paul has served as a consultant for AbbVie Pharmaceuticals, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Pierre Fabre. Dr Puig has served as an investigator for Amgen, Janssen Pharmaceuticals, LEO Pharma, Eli Lilly and Company, MSD, Pfizer Inc, and VBL Therapeutics; as a consultant for Amgen, Boehringer Ingelheim, Merck-Serono, and VBL Therapeutics; and as a consultant and speaker for AbbVie Pharmaceuticals, Celgene Corporation, Janssen Pharmaceuticals, LEO Pharma, MSD, and Pfizer Inc. Dr Reich has served as an investigator, advisory board member, speaker, and/or consultant for AbbVie Pharmaceuticals, Amgen, Biogen-Idec, Celgene Corporation, Centocor, Covagen, Eli Lilly and Company, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Medac Pharma, MSD, Novartis Pharmaceuticals Corporation, Ocean Pharma, Pfizer Inc, Takeda Pharmaceutical Company, and Vertex Pharmaceuticals. Dr van de Kerkhof has served as an investigator for Abbott Laboratories, Amgen, Basilea, Janssen-Cilag, Pfizer Inc, and Philips, and as a consultant for Abbott Laboratories, Almirall, Amgen, Celgene Corporation, Centocor, Eli Lilly and Company, Galderma, Janssen-Cilag, LEO Pharma, Pfizer Inc, and Philips. |
|
| Reprints are not available from the authors. |
Vol 70 - N° 5
P. 871 - mai 2014 Retour au numéro
Article précédent
- Commentary: Molecular testing in melanoma
- David M. Miller, Keith T. Flaherty, Hensin Tsao
- Increased serum levels of interleukin 33 in patients with atopic dermatitis
- Risa Tamagawa-Mineoka, Yasutaro Okuzawa, Koji Masuda, Norito Katoh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?